Recent clinical trials carried out in patients with
advanced cancer have shown that recombinant TRAIL
administration is usually safe and well tolerated when used
either alone or in association with chemotherapeutic drugs.
Notably, anticancer chemotherapy can be associated to
cardiomiopathy. We have here demonstrated that TRAIL
(administrated as either recombinant soluble TRAIL or as
AAV-TRAIL expression viral vector) reduced the development
of cardiomyopathy in the ApoE-/- diabetic mouse
model. These data suggest, for the first time, that
therapeutically administration of TRAIL might have a
cardioprotective effect.
